Patients with cancer and cancer survivors may have a higher risk of COVID-19 than the general population

The oral factor Xa inhibitor apixaban is noninferior to dalteparin for the treatment of venous thromboembolism in patients with cancer

A metastatic renal cell carcinoma patient who developed COVID-19 may have benefited from treatment with an IL-6 receptor inhibitor

Metastatic ablation might delay progression for some hormone-sensitive prostate cancer patients

Actions taken at a Chinese cancer hospital may have prevented the spread of SARS-CoV-2 and COVID-19

Certain pembrolizumab and nivolumab regimens have the lowest risks of being associated with immune-related adverse events in people with advanced melanoma

A scoring system can assess patients’ risk of dying within 90 days of completing concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma

Research sheds light on the risk of neurodegenerative disease after tamoxifen or aromatase inhibitor therapy